Determination of Free Triiodothyronine by Six Different Methods in Patients with Non-Thyroidal Illness and in Patients Treated with Amiodarone
- 1 May 1995
- journal article
- Published by SAGE Publications in Annals of Clinical Biochemistry: International Journal of Laboratory Medicine
- Vol. 32 (3) , 314-324
- https://doi.org/10.1177/000456329503200309
Abstract
We performed a methodological comparison of free triiodothyronine (FT3) estimates in patients with liver cirrhosis and renal failure. Patients were classified in terms of severity of illness on the basis of their total triiodothyronine, total thyroxine and reverse triiodothyronine profiles. FT3 levels, measured in direct dialysis, microchromatography, labelled analogue and two-step immunoextraction assays were significantly ( P < 0·01) lower than the control group in all patient categories. However, FT3 measured by a labelled antibody radioimmunoassay was significantly reduced only in the most severely ill sub-group of patients. In a further group of patients on long-term amiodarone therapy for cardiac disease all FT3 methods, with the exception of the labelled antibody radioimmunoassay and an analogue method, yielded significantly ( P < 0·01) reduced levels. A significant negative association between FT3 and subject age was demonstrated for all methods except the labelled antibody radioimmunoassay, and a weak but significant negative correlation between log thyrotropin and FT3 was only seen with this assay. Three methods demonstrated a correlation ( P < 0·02) with albumin levels in patients with the ‘low T3 syndrome’. In this group, albumin had a predictive value ( P ≤ 0·02) for four out of six assays as determined by stepwise variable selection. Our findings suggest that users of FT3 assays should exercise caution in interpreting results in non-thyroidal illness and amiodarone treated patients, as there are method-related differences in the profiles obtained.Keywords
This publication has 27 references indexed in Scilit:
- Thyroid Hormone Binding Inhibition in Critically ill Patients – Who is the Inhibitor?Experimental and Clinical Endocrinology & Diabetes, 1990
- Uptake of 3,5,3′-Triiodothyronine by the Perfused Rat Liver: Return to the Free Hormone Hypothesis*Endocrinology, 1988
- Serum thyroid hormone binding inhibitor in nonthyroidal illnessesMetabolism, 1986
- The Effect of Serum Dilution on Free Thyroxine (T4) Concentration in the Low T4Syndrome of Nonthyroidal IllnessJournal of Clinical Endocrinology & Metabolism, 1985
- Relationship between Serum Free Fatty Acids and Thyroid Hormone Binding Inhibitor in Nonthyroid Illnesses*Journal of Clinical Endocrinology & Metabolism, 1985
- Hypothyroxinemia in Critically III Patients as a Predictor of High MortalityJAMA, 1981
- Misleadingly Low Free Thyroxine Index and Usefulness of Reverse Triiodothyronine Measurement in Nonthyroidal IllnessesAnnals of Internal Medicine, 1979
- Abnormal thyroid function tests in severe non-thyroidal illness: diagnostic and pathophysiologic aspectsScandinavian Journal of Clinical and Laboratory Investigation, 1979
- Effect of amiodarone on serum triiodothyronine, reverse triiodothyronine, thyroxin, and thyrotropin. A drug influencing peripheral metabolism of thyroid hormones.Journal of Clinical Investigation, 1976
- EFFECT OF SEVERE, CHRONIC ILLNESS ON THYROID FUNCTIONThe Lancet, 1974